Clearmind Medicine DSMB backs continuing CMND-100 Phase I/IIa AUD trial at 160 mg dose
PUBT · 5d ago
Share
Listen to the news
- Clearmind Medicine received a positive Data and Safety Monitoring Board recommendation to continue its FDA-approved Phase I/IIa trial of CMND-100 in patients with moderate to severe Alcohol Use Disorder.
- Top-line safety results have already been presented internally to the board, showing CMND-100 was well tolerated with no serious adverse events reported.
- Clearmind will move into the fourth cohort, raising the dose to 160 mg.
- Trial is designed to assess safety and tolerability, pharmacokinetics, and early signs of efficacy for CMND-100, an oral non-hallucinogenic MEAI-based drug candidate.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150730PRIMZONEFULLFEED9690310) on April 15, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved